Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Comparative analysis of melphalan versus busulphan T-cell deplete conditioning using alemtuzumab in unrelated donor stem cell transplantation for acute myeloid leukaemia.

Sellar RS., Mehra V., Fox TA., Grigg A., Kulasekararaj A., Sarma A., de Lavallade H., McLornan D., Raj K., Mufti GJ., Pagliuca A., Mackinnon S., Chakraverty R., Fielding AK., Carpenter B., Kottaridis PD., Khwaja A., Peggs KS., Thomson KJ., Morris EC., Potter VT.

More information

DOI

10.1111/bjh.16136

Type

Journal article

Publication Date

01/10/2019

Volume

187

Pages

e20 - e24

Keywords

T-cell deplete conditioning, acute myeloid leukaemia, alemtuzumab, allogeneic stem cell transplant, Adult, Aged, Alemtuzumab, Busulfan, Female, Humans, Leukemia, Myeloid, Acute, Lymphocyte Depletion, Male, Melphalan, Middle Aged, Retrospective Studies, Survival Analysis, Transplantation Conditioning, Unrelated Donors, Young Adult